Washington, DC (November 10, 2021) – The Global Alzheimer’s Platform Foundation® (GAP) welcomes Lynne Hughes, PhD, an international clinical trial research expert, as a Senior Advisor to the organization. Dr. Hughes will further expand GAP’s strength in developing global networks of clinical trial research institutions dedicated to accelerating the discovery of new assessments, treatments, and cures for Alzheimer’s.
“Dr. Hughes will be an important contributor to GAP’s efforts to design more effective clinical trials and optimize the global clinical trial process,” said GAP President John Dwyer. “GAP’s mission to speed and improve Alzheimer’s clinical trials is an ambitious goal shared by Dr. Hughes. We are experiencing success in the United States and are eager to work with Dr. Hughes to take the GAP collaborative model, evidence-based approach and resources to create global clinical trial partnerships that will speed the discovery of therapeutics to those living with Alzheimer’s around the world.”
“GAP’s mission of optimizing the clinical trial process to be more efficient and accessible requires a robust international infrastructure to foster communication and resource distribution,” said Dr. Hughes. “My focus is to ensure researchers from around the world can work together, with urgency, to find an effective cure for Alzheimer’s. GAP brings together diverse perspectives that develop actionable solutions, and I am excited to join the GAP team and shape the Alzheimer’s clinical trials of the future.”
Dr. Hughes has managed and oversaw over 450 clinical trials in her career, including over 125 trials relating to Alzheimer’s some of which she designed and managed from concept through phase III. She spent 23 years with IQVIA working exclusively in neurology and held positions such as Vice President and Global Head of Medical Strategy for Neurology. Her final role at IQVIA was to develop evidence-based strategies for the most efficient conduct of clinical trials for global clients. Additionally, Dr. Hughes co-chaired the G20/World Economic Forum Alzheimer’s Collaboration initiative and has worked with various research organizations including The Gates Foundation.
###
About the Global Alzheimer’s Platform Foundation® (GAP) The Global Alzheimer’s Platform Foundation® (GAP) is a person-centric nonprofit dedicated to?accelerating?the delivery of innovative therapies for neurological disorders by reducing the?duration?and cost of clinical trials. Research centers?across the US, Canada, and Europe?are part of the growing GAP Network (GAP-Net). GAP supports?GAP-Net research centers by assisting with?study start up and recruitment activities,?promoting?diversity in research studies, and?offering?international clinical trial infrastructure, resources, and programs that champion brain health and the citizen scientists who make research possible.
Contact: Peter Buonanno – peterbuonanno@rational360.com, (704) 989-5501